Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma



Summary

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung cancer with limited treatment options. Recent research has aimed to comprehensively characterize LCNEC at both the molecular and clinical levels. Studies have identified frequent mutations in tumor suppressor genes like TP53 and RB1, along with alterations in pathways involved in cell cycle regulation and DNA damage repair. These molecular subtypes correlate with distinct clinical behaviors, response to chemotherapy, and overall survival. Integrated analysis of genomic, transcriptomic, and proteomic data alongside clinical information is crucial for developing personalized treatment strategies and improving outcomes for LCNEC patients.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!